Canada markets closed

Cingulate Inc. (CINGW)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.04000.0000 (0.00%)
At close: 10:43AM EST
Full screen
Loading interactive chart...
  • GlobeNewswire

    Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

    KANSAS CITY, Kan., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced that it has received guidance from the Food and Drug Administration (FDA) on advancing its investigational asset CTx-2103 (buspirone) for the treatment of anxiety into clinical development. “Cingulate received

  • GlobeNewswire

    Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

    Phase 3 Adult Efficacy and Safety Trial Data Presented at Psych Congress Cingulate Closed a $4M Public Offering $5.8M of Debt Converted into CING Equity KANSAS CITY, Kan., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate or the Company), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today provided financial results for the

  • GlobeNewswire

    Cingulate to Host CNS Key Opinion Leader Panel in New York City

    Expert Analysis of Cingulate, its Phase 3 ADHD Adult Data, Anxiety, and PTR™ Drug Delivery Platform InnovationsKANSAS CITY, Kan., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it will be hosting a key opinion leader event on the morning of October 23, 2023, at the